(Q77959593)

English

Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group

scientific article published on 01 December 1998

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

P E Donahue

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

D L Smith

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

A E Yellin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

S J Mintz

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

F Bur

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

D R Luke

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

language of work or name

0 references

publication date

1 December 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

The American Journal of Surgery

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

176

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

6A Suppl

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

53S-61S

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Intraabdominal infection: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Cefmetazole treatment of intra-abdominal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Treatment of intra-abdominal infections with quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

In vitro activity of the new fluoroquinolone CP-99,219.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

APACHE II: a severity of disease classification system

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Insurance-related differences in the risk of ruptured appendix

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Technique for calculation of the true costs of antibiotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

Imipenem in the treatment of severe bacterial infections in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900221-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9610(98)00221-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935258%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q77959593&oldid=1946519295"